Insider filing · LXRX

Raymond Debbane bought $277K of Lexicon Pharmaceuticals (LXRX)

Executed Feb 17, disclosed Feb 18, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Feb 18), the stock returned +19.1% (delay-adjusted); from the execution session (Feb 17), +22.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

RD Raymond Debbane Director profile →

Raymond Debbane (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in LXRX. Across 3 priced purchase filings, the average 21-session return was +11.5% from execution and +12.3% from disclosure (delay-adjusted; derived). The largest single filing was $277K of LXRX (210,545 sh across 2 lots, as filed), executed Feb 17.

LXRX LXRX LXRX · 4 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→